Patients with carotid atherosclerosis and type 2 diabetes or impaired glucose tolerance who took 15 to 30 milligrams of pioglitazone for four months attained similar fasting plasma glucose levels as those who took glimepiride, but showed significant improvements in atherosclerotic plaque inflammation compared with the glimepiride-treated group, according to a study in JACC: Cardiovascular Imaging. Researchers found that patients who took pioglitazone had increased levels of high-density lipoprotein, which may have helped to suppress atherosclerotic plaque.

Related Summaries